Overview

repotrectinib

kinase inhibitor

• CYP3A4 substrate
• P-gp substrate
• CYP3A4 inducer, moderate
• CNS depression
• hyperuricemic effects

Contraindicated

• lonafarnib
Augtyro (repotrectinib)

+

lonafarnib

1 interaction

Contraindicated

repotrectinib + lonafarnib

contraindicated: combo may incr. repotrectinib levels, risk of adverse effects; may decr. lonafarnib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• mavacamten
Augtyro (repotrectinib)

+

mavacamten

1 interaction

Contraindicated

repotrectinib + mavacamten

contraindicated: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• ranolazine
Augtyro (repotrectinib)

+

ranolazine

1 interaction

Contraindicated

repotrectinib + ranolazine

contraindicated: combo may decr. ranolazine levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited, P-gp-mediated transport inhibited)

Avoid/Use Alternative

• abemaciclib
Augtyro (repotrectinib)

+

abemaciclib

1 interaction

Avoid/Use Alternative

repotrectinib + abemaciclib

avoid combo: combo may decr. abemaciclib levels, efficacy (hepatic metab. induced)

• abrocitinib
Augtyro (repotrectinib)

+

abrocitinib

1 interaction

Avoid/Use Alternative

repotrectinib + abrocitinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• adagrasib
Augtyro (repotrectinib)

+

adagrasib

1 interaction

Avoid/Use Alternative

repotrectinib + adagrasib

avoid combo; D/C adagrasib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. adagrasib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• alfentanil
Augtyro (repotrectinib)

+

alfentanil

1 interaction

Avoid/Use Alternative

repotrectinib + alfentanil

use alternative or consider alfentanil dose adjustment; monitor BP, resp. rate: combo may decr. alfentanil levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension (hepatic metab. induced; additive effects)

• alpelisib
Augtyro (repotrectinib)

+

alpelisib

1 interaction

Avoid/Use Alternative

repotrectinib + alpelisib

consider alternative: combo may decr. alpelisib levels, efficacy (hepatic metab. induced)

• amiodarone
Augtyro (repotrectinib)

+

amiodarone

1 interaction

Avoid/Use Alternative

repotrectinib + amiodarone

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. amiodarone levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• apalutamide
Augtyro (repotrectinib)

+

apalutamide

1 interaction

Avoid/Use Alternative

repotrectinib + apalutamide

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• aprepitant
Augtyro (repotrectinib)

+

aprepitant

1 interaction

Avoid/Use Alternative

repotrectinib + aprepitant

avoid combo; D/C aprepitant 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. aprepitant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• artemether/lumefantrine
Augtyro (repotrectinib)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

repotrectinib + artemether/ lumefantrine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• asciminib
Augtyro (repotrectinib)

+

asciminib

1 interaction

Avoid/Use Alternative

repotrectinib + asciminib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited)

• atazanavir
Augtyro (repotrectinib)

+

atazanavir

1 interaction

Avoid/Use Alternative

repotrectinib + atazanavir

avoid combo; D/C atazanavir 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. atazanavir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• atogepant
Augtyro (repotrectinib)

+

atogepant

1 interaction

Avoid/Use Alternative

repotrectinib + atogepant

CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metab. induced)

• atrasentan
Augtyro (repotrectinib)

+

atrasentan

1 interaction

Avoid/Use Alternative

repotrectinib + atrasentan

avoid combo: combo may decr. atrasentan levels, efficacy (hepatic metab. induced)

• avacopan
Augtyro (repotrectinib)

+

avacopan

1 interaction

Avoid/Use Alternative

repotrectinib + avacopan

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• avapritinib
Augtyro (repotrectinib)

+

avapritinib

1 interaction

Avoid/Use Alternative

repotrectinib + avapritinib

avoid combo: combo may decr. avapritinib levels, efficacy (hepatic metab. induced)

• axitinib
Augtyro (repotrectinib)

+

axitinib

1 interaction

Avoid/Use Alternative

repotrectinib + axitinib

avoid combo: combo may decr. axitinib levels, efficacy (hepatic metab. induced)

• azithromycin
Augtyro (repotrectinib)

+

azithromycin

1 interaction

Avoid/Use Alternative

repotrectinib + azithromycin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• bedaquiline
Augtyro (repotrectinib)

+

bedaquiline

1 interaction

Avoid/Use Alternative

repotrectinib + bedaquiline

avoid combo: combo may decr. bedaquiline levels, efficacy (hepatic metab. induced)

• belumosudil
Augtyro (repotrectinib)

+

belumosudil

1 interaction

Avoid/Use Alternative

repotrectinib + belumosudil

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. belumosudil levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• berotralstat
Augtyro (repotrectinib)

+

berotralstat

1 interaction

Avoid/Use Alternative

repotrectinib + berotralstat

avoid combo; D/C berotralstat 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• bictegravir
Augtyro (repotrectinib)

+

bictegravir

1 interaction

Avoid/Use Alternative

repotrectinib + bictegravir

use alternative if also combined w/ UGT1A1 inducer: combo may decr. bictegravir levels, efficacy (hepatic metab. induced)

• bisoprolol
Augtyro (repotrectinib)

+

bisoprolol

1 interaction

Avoid/Use Alternative

repotrectinib + bisoprolol

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• bosentan
Augtyro (repotrectinib)

+

bosentan

1 interaction

Avoid/Use Alternative

repotrectinib + bosentan

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• bosutinib
Augtyro (repotrectinib)

+

bosutinib

1 interaction

Avoid/Use Alternative

repotrectinib + bosutinib

avoid combo: combo may decr. bosutinib levels, efficacy (hepatic metab. induced)

• brigatinib
Augtyro (repotrectinib)

+

brigatinib

1 interaction

Avoid/Use Alternative

repotrectinib + brigatinib

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr. brigatinib levels, efficacy (P-gp-mediated transport possibly inhibited, hepatic metab. induced; hepatic metab. induced)

• buprenorphine
Augtyro (repotrectinib)

+

buprenorphine

1 interaction

Avoid/Use Alternative

repotrectinib + buprenorphine

use alternative or monitor withdrawal sx, resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. buprenorphine levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• buspirone
Augtyro (repotrectinib)

+

buspirone

1 interaction

Avoid/Use Alternative

repotrectinib + buspirone

consider alternative or adjust buspirone dose: combo may decr. buspirone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• butalbital
Augtyro (repotrectinib)

+

butalbital

1 interaction

Avoid/Use Alternative

repotrectinib + butalbital

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• cabozantinib
Augtyro (repotrectinib)

+

cabozantinib

1 interaction

Avoid/Use Alternative

repotrectinib + cabozantinib

use alternative or incr. cabozantinib daily dose by 20 mg if renal cell CA, hepatocellular CA, differentiated thyroid CA, or NET use; consider cabozantinib dose adjustment if medullary thyroid CA use: combo may decr. cabozantinib levels, efficacy (hepatic metab. induced)

• canagliflozin
Augtyro (repotrectinib)

+

canagliflozin

1 interaction

Avoid/Use Alternative

repotrectinib + canagliflozin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• cannabidiol
Augtyro (repotrectinib)

+

cannabidiol

1 interaction

Avoid/Use Alternative

repotrectinib + cannabidiol

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects (gut P-gp-mediated transport inhibited, additive effects)

• capivasertib
Augtyro (repotrectinib)

+

capivasertib

1 interaction

Avoid/Use Alternative

repotrectinib + capivasertib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• capmatinib
Augtyro (repotrectinib)

+

capmatinib

1 interaction

Avoid/Use Alternative

repotrectinib + capmatinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. capmatinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• captopril
Augtyro (repotrectinib)

+

captopril

1 interaction

Avoid/Use Alternative

repotrectinib + captopril

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• carbamazepine
Augtyro (repotrectinib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

repotrectinib + carbamazepine

avoid combo: combo may decr. levels of both drugs, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• cariprazine
Augtyro (repotrectinib)

+

cariprazine

1 interaction

Avoid/Use Alternative

repotrectinib + cariprazine

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• carvedilol
Augtyro (repotrectinib)

+

carvedilol

1 interaction

Avoid/Use Alternative

repotrectinib + carvedilol

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• cenobamate
Augtyro (repotrectinib)

+

cenobamate

1 interaction

Avoid/Use Alternative

repotrectinib + cenobamate

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• ceritinib
Augtyro (repotrectinib)

+

ceritinib

1 interaction

Avoid/Use Alternative

repotrectinib + ceritinib

avoid combo; D/C ceritinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ceritinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• chloramphenicol
Augtyro (repotrectinib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

repotrectinib + chloramphenicol

avoid combo; D/C chloramphenicol 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• cimetidine
Augtyro (repotrectinib)

+

cimetidine

1 interaction

Avoid/Use Alternative

repotrectinib + cimetidine

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• ciprofloxacin
Augtyro (repotrectinib)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

repotrectinib + ciprofloxacin

avoid combo; D/C ciprofloxacin 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• clarithromycin
Augtyro (repotrectinib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

repotrectinib + clarithromycin

avoid combo; D/C clarithromycin 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. clarithromycin levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• clofazimine
Augtyro (repotrectinib)

+

clofazimine

1 interaction

Avoid/Use Alternative

repotrectinib + clofazimine

avoid combo; D/C clofazimine 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• clonidine
Augtyro (repotrectinib)

+

clonidine

1 interaction

Avoid/Use Alternative

repotrectinib + clonidine

if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cobicistat
Augtyro (repotrectinib)

+

cobicistat

1 interaction

Avoid/Use Alternative

repotrectinib + cobicistat

avoid combo; D/C cobicistat 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. cobicistat levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• cobimetinib
Augtyro (repotrectinib)

+

cobimetinib

1 interaction

Avoid/Use Alternative

repotrectinib + cobimetinib

avoid combo: combo may decr. cobimetinib levels, efficacy (hepatic metab. induced)

• codeine
Augtyro (repotrectinib)

+

codeine

1 interaction

Avoid/Use Alternative

repotrectinib + codeine

avoid combo if antitussive use; otherwise, use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. codeine and active metabolite morphine levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced, may decr. production of active metabolite morphine; additive effects)

• conivaptan
Augtyro (repotrectinib)

+

conivaptan

1 interaction

Avoid/Use Alternative

repotrectinib + conivaptan

avoid combo during and x7 days after conivaptan tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• crizotinib
Augtyro (repotrectinib)

+

crizotinib

1 interaction

Avoid/Use Alternative

repotrectinib + crizotinib

avoid combo; D/C crizotinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. crizotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• cyclosporine
Augtyro (repotrectinib)

+

cyclosporine

1 interaction

Avoid/Use Alternative

repotrectinib + cyclosporine

avoid combo; D/C cyclosporine 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. cyclosporine levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• dabrafenib
Augtyro (repotrectinib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

repotrectinib + dabrafenib

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• danazol
Augtyro (repotrectinib)

+

danazol

1 interaction

Avoid/Use Alternative

repotrectinib + danazol

avoid combo; D/C danazol 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• danicopan
Augtyro (repotrectinib)

+

danicopan

1 interaction

Avoid/Use Alternative

repotrectinib + danicopan

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• daridorexant
Augtyro (repotrectinib)

+

daridorexant

1 interaction

Avoid/Use Alternative

repotrectinib + daridorexant

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. daridorexant levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• darolutamide
Augtyro (repotrectinib)

+

darolutamide

1 interaction

Avoid/Use Alternative

repotrectinib + darolutamide

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• darunavir
Augtyro (repotrectinib)

+

darunavir

1 interaction

Avoid/Use Alternative

repotrectinib + darunavir

avoid combo; D/C darunavir 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. darunavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• defactinib
Augtyro (repotrectinib)

+

defactinib

1 interaction

Avoid/Use Alternative

repotrectinib + defactinib

avoid combo: combo may decr. defactinib levels, efficacy (hepatic metab. induced)

• deflazacort
Augtyro (repotrectinib)

+

deflazacort

1 interaction

Avoid/Use Alternative

repotrectinib + deflazacort

avoid combo: combo may decr. deflazacort active metabolite levels, efficacy (hepatic metab. induced)

• desogestrel (contraceptive)
Augtyro (repotrectinib)

+

desogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + desogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. desogestrel levels, contraceptive efficacy (hepatic metab. induced)

• diazoxide
Augtyro (repotrectinib)

+

diazoxide

1 interaction

Avoid/Use Alternative

repotrectinib + diazoxide

avoid combo if also combined w/ moderate or strong CYP1A2 inducer; otherwise, caution advised: combo may decr. diazoxide levels, efficacy (hepatic metab. induced)

• dienogest (contraceptive)
Augtyro (repotrectinib)

+

dienogest (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + dienogest (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. dienogest levels, contraceptive efficacy (hepatic metab. induced)

• dihydrocodeine
Augtyro (repotrectinib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

repotrectinib + dihydrocodeine

use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. dihydrocodeine and active metabolite dihydromorphine levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced, may decr. production of active metabolite dihydromorphine; additive effects)

• diltiazem
Augtyro (repotrectinib)

+

diltiazem

1 interaction

Avoid/Use Alternative

repotrectinib + diltiazem

avoid combo; D/C diltiazem 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. diltiazem levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• diosmin
Augtyro (repotrectinib)

+

diosmin

1 interaction

Avoid/Use Alternative

repotrectinib + diosmin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• dolutegravir
Augtyro (repotrectinib)

+

dolutegravir

1 interaction

Avoid/Use Alternative

repotrectinib + dolutegravir

avoid combo: combo may decr. dolutegravir levels, efficacy (hepatic metab. induced)

• doravirine
Augtyro (repotrectinib)

+

doravirine

1 interaction

Avoid/Use Alternative

repotrectinib + doravirine

avoid combo: combo may decr. doravirine levels, efficacy (hepatic metab. induced)

• doxorubicin
Augtyro (repotrectinib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

repotrectinib + doxorubicin

avoid combo: combo may decr. doxorubicin levels, efficacy (hepatic metab. induced)

• doxylamine
Augtyro (repotrectinib)

+

doxylamine

1 interaction

Avoid/Use Alternative

repotrectinib + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronedarone
Augtyro (repotrectinib)

+

dronedarone

1 interaction

Avoid/Use Alternative

repotrectinib + dronedarone

avoid combo; D/C dronedarone 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• drospirenone (contraceptive)
Augtyro (repotrectinib)

+

drospirenone (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + drospirenone (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. drospirenone levels, contraceptive efficacy (hepatic metab. induced)

• duvelisib
Augtyro (repotrectinib)

+

duvelisib

1 interaction

Avoid/Use Alternative

repotrectinib + duvelisib

avoid combo; D/C duvelisib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. duvelisib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• efavirenz
Augtyro (repotrectinib)

+

efavirenz

1 interaction

Avoid/Use Alternative

repotrectinib + efavirenz

avoid combo: combo may decr. levels of both drugs, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• elacestrant
Augtyro (repotrectinib)

+

elacestrant

1 interaction

Avoid/Use Alternative

repotrectinib + elacestrant

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. elacestrant levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• elagolix
Augtyro (repotrectinib)

+

elagolix

1 interaction

Avoid/Use Alternative

repotrectinib + elagolix

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

• elbasvir
Augtyro (repotrectinib)

+

elbasvir

1 interaction

Avoid/Use Alternative

repotrectinib + elbasvir

avoid combo: combo may decr. elbasvir levels, efficacy (hepatic metab. induced)

• elexacaftor/tezacaftor/ivacaftor
Augtyro (repotrectinib)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

repotrectinib + elexacaftor/ tezacaftor/ ivacaftor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. elexacaftor/tezacaftor/ivacaftor levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• eliglustat
Augtyro (repotrectinib)

+

eliglustat

1 interaction

Avoid/Use Alternative

repotrectinib + eliglustat

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. eliglustat levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• elvitegravir
Augtyro (repotrectinib)

+

elvitegravir

1 interaction

Avoid/Use Alternative

repotrectinib + elvitegravir

avoid combo: combo may decr. elvitegravir levels, efficacy (hepatic metab. induced)

• enasidenib
Augtyro (repotrectinib)

+

enasidenib

1 interaction

Avoid/Use Alternative

repotrectinib + enasidenib

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

• encorafenib
Augtyro (repotrectinib)

+

encorafenib

1 interaction

Avoid/Use Alternative

repotrectinib + encorafenib

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• ensartinib
Augtyro (repotrectinib)

+

ensartinib

1 interaction

Avoid/Use Alternative

repotrectinib + ensartinib

avoid combo: combo may decr. ensartinib levels, efficacy (hepatic metab. possibly induced)

• entrectinib
Augtyro (repotrectinib)

+

entrectinib

1 interaction

Avoid/Use Alternative

repotrectinib + entrectinib

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. entrectinib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• enzalutamide
Augtyro (repotrectinib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

repotrectinib + enzalutamide

avoid combo: combo may decr. levels of both drugs, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; P-gp-mediated transport inhibited)

• erdafitinib
Augtyro (repotrectinib)

+

erdafitinib

1 interaction

Avoid/Use Alternative

repotrectinib + erdafitinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. erdafitinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• erlotinib
Augtyro (repotrectinib)

+

erlotinib

1 interaction

Avoid/Use Alternative

repotrectinib + erlotinib

use alternative or incr. erlotinib dose by 50mg/day q2wk up to 450 mg/day: combo may decr. erlotinib levels, efficacy (hepatic metab. induced)

• erythromycin
Augtyro (repotrectinib)

+

erythromycin

1 interaction

Avoid/Use Alternative

repotrectinib + erythromycin

avoid combo; D/C erythromycin 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. erythromycin levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• estradiol (contraceptive)
Augtyro (repotrectinib)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. estradiol levels, contraceptive efficacy (hepatic metab. induced)

• ethanol
Augtyro (repotrectinib)

+

ethanol

1 interaction

Avoid/Use Alternative

repotrectinib + ethanol

avoid combo: coingestion of oral alcohol w/ repotrectinib may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• ethinyl estradiol (contraceptive)
Augtyro (repotrectinib)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• ethynodiol (contraceptive)
Augtyro (repotrectinib)

+

ethynodiol (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + ethynodiol (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. ethynodiol and active metabolite levels, contraceptive efficacy (hepatic metab. induced)

• etonogestrel (contraceptive)
Augtyro (repotrectinib)

+

etonogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + etonogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. etonogestrel levels, contraceptive efficacy (hepatic metab. induced)

• etravirine
Augtyro (repotrectinib)

+

etravirine

1 interaction

Avoid/Use Alternative

repotrectinib + etravirine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• everolimus
Augtyro (repotrectinib)

+

everolimus

1 interaction

Avoid/Use Alternative

repotrectinib + everolimus

BREAST CA, PNET, RENAL CELL CA, RENAL ANGIOMYOLIPOMA W/ TSC: if also combined w/ P-gp inducer, use alternative or double everolimus dose using increments of 5 mg or less; otherwise, caution advised; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inducer, double everolimus dose using increments of 5 mg or less and monitor everolimus levels; otherwise, monitor everolimus levels; TRANSPLANT: use alternative or monitor everolimus levels: combo may decr. everolimus levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• fedratinib
Augtyro (repotrectinib)

+

fedratinib

1 interaction

Avoid/Use Alternative

repotrectinib + fedratinib

avoid combo; D/C fedratinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. fedratinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• felodipine
Augtyro (repotrectinib)

+

felodipine

1 interaction

Avoid/Use Alternative

repotrectinib + felodipine

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. felodipine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• fentanyl
Augtyro (repotrectinib)

+

fentanyl

1 interaction

Avoid/Use Alternative

repotrectinib + fentanyl

use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. fentanyl levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• fexinidazole
Augtyro (repotrectinib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

repotrectinib + fexinidazole

avoid combo: combo may incr. fexinidazole active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. repotrectinib levels, efficacy (hepatic metab. induced, incr. conversion to active metabolites)

• finerenone
Augtyro (repotrectinib)

+

finerenone

1 interaction

Avoid/Use Alternative

repotrectinib + finerenone

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. finerenone levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• flibanserin
Augtyro (repotrectinib)

+

flibanserin

1 interaction

Avoid/Use Alternative

repotrectinib + flibanserin

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. flibanserin levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• fluconazole
Augtyro (repotrectinib)

+

fluconazole

1 interaction

Avoid/Use Alternative

repotrectinib + fluconazole

avoid combo; D/C fluconazole 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• fluvoxamine
Augtyro (repotrectinib)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

repotrectinib + fluvoxamine

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse reactions (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• fosamprenavir
Augtyro (repotrectinib)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

repotrectinib + fosamprenavir

avoid combo; D/C fosamprenavir 3-5 half-lives prior to repotrectinib tx: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr. amprenavir levels (hepatic metab. altered; hepatic metab. induced)

• fosaprepitant
Augtyro (repotrectinib)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

repotrectinib + fosaprepitant

avoid combo: combo may decr. levels of both drugs, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• fosphenytoin
Augtyro (repotrectinib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

repotrectinib + fosphenytoin

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• fostamatinib
Augtyro (repotrectinib)

+

fostamatinib

1 interaction

Avoid/Use Alternative

repotrectinib + fostamatinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. fostamatinib active metabolite levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• fruquintinib
Augtyro (repotrectinib)

+

fruquintinib

1 interaction

Avoid/Use Alternative

repotrectinib + fruquintinib

use alternative: combo may decr. fruquintinib levels, efficacy (hepatic metab. induced)

• futibatinib
Augtyro (repotrectinib)

+

futibatinib

1 interaction

Avoid/Use Alternative

repotrectinib + futibatinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. futibatinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• ganaxolone
Augtyro (repotrectinib)

+

ganaxolone

1 interaction

Avoid/Use Alternative

repotrectinib + ganaxolone

use alternative or consider ganaxolone dose adjustment: combo may decr. ganaxolone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• gilteritinib
Augtyro (repotrectinib)

+

gilteritinib

1 interaction

Avoid/Use Alternative

repotrectinib + gilteritinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. gilteritinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• ginkgo
Augtyro (repotrectinib)

+

ginkgo

1 interaction

Avoid/Use Alternative

repotrectinib + ginkgo

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or efficacy (hepatic metab. altered, P-gp-mediated transport inhibited)

• glasdegib
Augtyro (repotrectinib)

+

glasdegib

1 interaction

Avoid/Use Alternative

repotrectinib + glasdegib

use alternative or incr. glasdegib dose as follows: if on glasdegib 100 mg qd, incr. to 200 mg qd; if on glasdegib 50 mg qd, incr. to 100 mg qd: combo may decr. glasdegib levels, efficacy (hepatic metab. induced)

• glecaprevir
Augtyro (repotrectinib)

+

glecaprevir

1 interaction

Avoid/Use Alternative

repotrectinib + glecaprevir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. glecaprevir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• grapefruit
Augtyro (repotrectinib)

+

grapefruit

1 interaction

Avoid/Use Alternative

repotrectinib + grapefruit

avoid grapefruit juice: combo may incr. repotrectinib levels, risk of adverse effects (GI metab. inhibited)

• grazoprevir
Augtyro (repotrectinib)

+

grazoprevir

1 interaction

Avoid/Use Alternative

repotrectinib + grazoprevir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. grazoprevir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• hydrocodone
Augtyro (repotrectinib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

repotrectinib + hydrocodone

avoid combo if antitussive use; otherwise, use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. hydrocodone levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• ibrexafungerp
Augtyro (repotrectinib)

+

ibrexafungerp

1 interaction

Avoid/Use Alternative

repotrectinib + ibrexafungerp

avoid combo: combo may decr. ibrexafungerp levels, efficacy (hepatic metab. induced)

• ibrutinib
Augtyro (repotrectinib)

+

ibrutinib

1 interaction

Avoid/Use Alternative

repotrectinib + ibrutinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ibrutinib levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• idelalisib
Augtyro (repotrectinib)

+

idelalisib

1 interaction

Avoid/Use Alternative

repotrectinib + idelalisib

avoid combo; D/C idelalisib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. idelalisib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• imatinib
Augtyro (repotrectinib)

+

imatinib

1 interaction

Avoid/Use Alternative

repotrectinib + imatinib

avoid combo; D/C imatinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. imatinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• indomethacin
Augtyro (repotrectinib)

+

indomethacin

1 interaction

Avoid/Use Alternative

repotrectinib + indomethacin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• irinotecan
Augtyro (repotrectinib)

+

irinotecan

1 interaction

Avoid/Use Alternative

repotrectinib + irinotecan

use alternative or D/C repotrectinib >2wk prior to irinotecan start: combo may decr. irinotecan and active metabolite levels, efficacy (hepatic metab. induced)

• isavuconazonium
Augtyro (repotrectinib)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

repotrectinib + isavuconazonium

avoid combo; D/C isavuconazole 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. isavuconazole levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• isocarboxazid
Augtyro (repotrectinib)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

repotrectinib + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• isradipine
Augtyro (repotrectinib)

+

isradipine

1 interaction

Avoid/Use Alternative

repotrectinib + isradipine

consider alternative: combo may decr. isradipine levels, efficacy (hepatic metab. induced)

• istradefylline
Augtyro (repotrectinib)

+

istradefylline

1 interaction

Avoid/Use Alternative

repotrectinib + istradefylline

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. istradefylline levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• itraconazole
Augtyro (repotrectinib)

+

itraconazole

1 interaction

Avoid/Use Alternative

repotrectinib + itraconazole

avoid combo 2wk before, during, and 2wk after itraconazole tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. itraconazole levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• ivacaftor
Augtyro (repotrectinib)

+

ivacaftor

1 interaction

Avoid/Use Alternative

repotrectinib + ivacaftor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ivacaftor levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• ivosidenib
Augtyro (repotrectinib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

repotrectinib + ivosidenib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• kava
Augtyro (repotrectinib)

+

kava

1 interaction

Avoid/Use Alternative

repotrectinib + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ketoconazole
Augtyro (repotrectinib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

repotrectinib + ketoconazole

avoid combo 2wk before, during and up to 1wk after ketoconazole tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ketoconazole levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• kratom
Augtyro (repotrectinib)

+

kratom

1 interaction

Avoid/Use Alternative

repotrectinib + kratom

use alternative or monitor resp. rate: combo may incr. repotrectinib levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• lapatinib
Augtyro (repotrectinib)

+

lapatinib

1 interaction

Avoid/Use Alternative

repotrectinib + lapatinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. lapatinib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• larotrectinib
Augtyro (repotrectinib)

+

larotrectinib

1 interaction

Avoid/Use Alternative

repotrectinib + larotrectinib

use alternative or double larotrectinib dose: combo may decr. larotrectinib levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• lasmiditan
Augtyro (repotrectinib)

+

lasmiditan

1 interaction

Avoid/Use Alternative

repotrectinib + lasmiditan

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• lazertinib
Augtyro (repotrectinib)

+

lazertinib

1 interaction

Avoid/Use Alternative

repotrectinib + lazertinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. lazertinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• ledipasvir
Augtyro (repotrectinib)

+

ledipasvir

1 interaction

Avoid/Use Alternative

repotrectinib + ledipasvir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• lefamulin
Augtyro (repotrectinib)

+

lefamulin

1 interaction

Avoid/Use Alternative

repotrectinib + lefamulin

ORAL LEFAMULIN: avoid combo; D/C lefamulin 3-5 half-lives prior to repotrectinib tx; IV LEFAMULIN: caution advised: combo may incr. repotrectinib levels, risk of adverse effects; may decr. lefamulin levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• lemborexant
Augtyro (repotrectinib)

+

lemborexant

1 interaction

Avoid/Use Alternative

repotrectinib + lemborexant

avoid combo: combo may decr. lemborexant levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• lenacapavir
Augtyro (repotrectinib)

+

lenacapavir

1 interaction

Avoid/Use Alternative

repotrectinib + lenacapavir

avoid combo during and x9mo after lenacapavir tx; D/C lenacapavir 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. lenacapavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• leniolisib
Augtyro (repotrectinib)

+

leniolisib

1 interaction

Avoid/Use Alternative

repotrectinib + leniolisib

avoid combo: combo may decr. leniolisib levels, efficacy (hepatic metab. induced)

• letermovir
Augtyro (repotrectinib)

+

letermovir

1 interaction

Avoid/Use Alternative

repotrectinib + letermovir

avoid combo; D/C letermovir 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. letermovir levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• levacetylleucine
Augtyro (repotrectinib)

+

levacetylleucine

1 interaction

Avoid/Use Alternative

repotrectinib + levacetylleucine

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• levoketoconazole
Augtyro (repotrectinib)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

repotrectinib + levoketoconazole

avoid combo x2wk before and during levoketoconazole tx; D/C levoketoconazole 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. levoketoconazole levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• levonorgestrel (contraceptive)
Augtyro (repotrectinib)

+

levonorgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + levonorgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metab. induced)

• levonorgestrel (post-coital contraceptive)
Augtyro (repotrectinib)

+

levonorgestrel (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + levonorgestrel (post-coital contraceptive)

consider alternative: combo may decr. levonorgestrel levels, post-coital contraceptive efficacy (hepatic metab. induced)

• lomitapide
Augtyro (repotrectinib)

+

lomitapide

1 interaction

Avoid/Use Alternative

repotrectinib + lomitapide

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, gut P-gp-mediated transport inhibited)

• lopinavir/ritonavir
Augtyro (repotrectinib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

repotrectinib + lopinavir/ ritonavir

avoid combo; D/C lopinavir/ritonavir 3-5 half-lives prior to repotrectinib tx: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr. lopinavir/ritonavir levels, efficacy (hepatic metab. altered, P-gp-mediated transport inhibited; hepatic metab. induced)

• lorlatinib
Augtyro (repotrectinib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

repotrectinib + lorlatinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• lumacaftor/ivacaftor
Augtyro (repotrectinib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

repotrectinib + lumacaftor/ ivacaftor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. levels of both drugs, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• lumateperone
Augtyro (repotrectinib)

+

lumateperone

1 interaction

Avoid/Use Alternative

repotrectinib + lumateperone

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• macitentan
Augtyro (repotrectinib)

+

macitentan

1 interaction

Avoid/Use Alternative

repotrectinib + macitentan

avoid combo: combo may decr. macitentan levels, efficacy (hepatic metab. induced)

• maraviroc
Augtyro (repotrectinib)

+

maraviroc

1 interaction

Avoid/Use Alternative

repotrectinib + maraviroc

ADULTS: adjust maraviroc dose to 600 mg bid; if also combined w/ strong CYP3A4 inhibitor, adjust maraviroc dose to 150 mg bid; PEDS: avoid combo: combo may decr. maraviroc levels, efficacy (hepatic metab. induced)

• maribavir
Augtyro (repotrectinib)

+

maribavir

1 interaction

Avoid/Use Alternative

repotrectinib + maribavir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. maribavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• mavorixafor
Augtyro (repotrectinib)

+

mavorixafor

1 interaction

Avoid/Use Alternative

repotrectinib + mavorixafor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. mavorixafor levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• medroxyprogesterone (contraceptive)
Augtyro (repotrectinib)

+

medroxyprogesterone (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + medroxyprogesterone (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. medroxyprogesterone levels, contraceptive efficacy (hepatic metab. induced)

• meperidine
Augtyro (repotrectinib)

+

meperidine

1 interaction

Avoid/Use Alternative

repotrectinib + meperidine

use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced, incr. toxic metabolite formation; additive effects)

• metaxalone
Augtyro (repotrectinib)

+

metaxalone

1 interaction

Avoid/Use Alternative

repotrectinib + metaxalone

use alternative or monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methadone
Augtyro (repotrectinib)

+

methadone

1 interaction

Avoid/Use Alternative

repotrectinib + methadone

use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. methadone levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• metoclopramide
Augtyro (repotrectinib)

+

metoclopramide

1 interaction

Avoid/Use Alternative

repotrectinib + metoclopramide

use alternative: combo may decr. metoclopramide levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• midazolam
Augtyro (repotrectinib)

+

midazolam

1 interaction

Avoid/Use Alternative

repotrectinib + midazolam

use alternative or monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may decr. midazolam levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• midostaurin
Augtyro (repotrectinib)

+

midostaurin

1 interaction

Avoid/Use Alternative

repotrectinib + midostaurin

consider alternative: combo may decr. midostaurin levels, efficacy (hepatic metab. induced)

• mifepristone
Augtyro (repotrectinib)

+

mifepristone

1 interaction

Avoid/Use Alternative

repotrectinib + mifepristone

avoid combo during and x14 days after daily mifepristone use; caution advised if pregnancy termination use: combo may incr. repotrectinib levels, risk of adverse effects; may decr. mifepristone levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• milk thistle
Augtyro (repotrectinib)

+

milk thistle

1 interaction

Avoid/Use Alternative

repotrectinib + milk thistle

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• mirabegron
Augtyro (repotrectinib)

+

mirabegron

1 interaction

Avoid/Use Alternative

repotrectinib + mirabegron

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• mitapivat
Augtyro (repotrectinib)

+

mitapivat

1 interaction

Avoid/Use Alternative

repotrectinib + mitapivat

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr mitapivat levels, efficacy (hepatic metab. induced, P-gp-mediated transport inhibited; hepatic metab. induced)

• mitotane
Augtyro (repotrectinib)

+

mitotane

1 interaction

Avoid/Use Alternative

repotrectinib + mitotane

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• mobocertinib
Augtyro (repotrectinib)

+

mobocertinib

1 interaction

Avoid/Use Alternative

repotrectinib + mobocertinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• modafinil
Augtyro (repotrectinib)

+

modafinil

1 interaction

Avoid/Use Alternative

repotrectinib + modafinil

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• nafcillin
Augtyro (repotrectinib)

+

nafcillin

1 interaction

Avoid/Use Alternative

repotrectinib + nafcillin

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• naldemedine
Augtyro (repotrectinib)

+

naldemedine

1 interaction

Avoid/Use Alternative

repotrectinib + naldemedine

use alternative: combo may decr. naldemedine levels, efficacy (hepatic metab. induced)

• naloxegol
Augtyro (repotrectinib)

+

naloxegol

1 interaction

Avoid/Use Alternative

repotrectinib + naloxegol

consider alternative: combo may decr. naloxegol levels, efficacy (hepatic metab. induced)

• naproxen
Augtyro (repotrectinib)

+

naproxen

1 interaction

Avoid/Use Alternative

repotrectinib + naproxen

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• nefazodone
Augtyro (repotrectinib)

+

nefazodone

1 interaction

Avoid/Use Alternative

repotrectinib + nefazodone

avoid combo; D/C nefazodone 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. nefazodone levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• nelfinavir
Augtyro (repotrectinib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

repotrectinib + nelfinavir

avoid combo; D/C nelfinavir 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. nelfinavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• neratinib
Augtyro (repotrectinib)

+

neratinib

1 interaction

Avoid/Use Alternative

repotrectinib + neratinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. neratinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• netupitant
Augtyro (repotrectinib)

+

netupitant

1 interaction

Avoid/Use Alternative

repotrectinib + netupitant

avoid combo during and x1wk after (fos)netupitant tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. netupitant levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• nevirapine
Augtyro (repotrectinib)

+

nevirapine

1 interaction

Avoid/Use Alternative

repotrectinib + nevirapine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• nicardipine
Augtyro (repotrectinib)

+

nicardipine

1 interaction

Avoid/Use Alternative

repotrectinib + nicardipine

use alternative or monitor BP: combo may incr. repotrectinib levels, risk of adverse effects; may decr. nicardipine levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• nifedipine
Augtyro (repotrectinib)

+

nifedipine

1 interaction

Avoid/Use Alternative

repotrectinib + nifedipine

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. nifedipine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• nilotinib
Augtyro (repotrectinib)

+

nilotinib

1 interaction

Avoid/Use Alternative

repotrectinib + nilotinib

avoid combo; D/C nilotinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• nirmatrelvir
Augtyro (repotrectinib)

+

nirmatrelvir

1 interaction

Avoid/Use Alternative

repotrectinib + nirmatrelvir

avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metab. induced)

• nirogacestat
Augtyro (repotrectinib)

+

nirogacestat

1 interaction

Avoid/Use Alternative

repotrectinib + nirogacestat

avoid combo; D/C nirogacetat 3-5 half-lives prior to repotrectinib tx: combo may decr. nirogacestat levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• nisoldipine
Augtyro (repotrectinib)

+

nisoldipine

1 interaction

Avoid/Use Alternative

repotrectinib + nisoldipine

use alternative or monitor BP: combo may decr. nisoldipine levels, efficacy (hepatic metab. induced)

• norelgestromin (contraceptive)
Augtyro (repotrectinib)

+

norelgestromin (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + norelgestromin (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. norelgestromin levels, contraceptive efficacy (hepatic metab. induced)

• norethindrone (contraceptive)
Augtyro (repotrectinib)

+

norethindrone (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + norethindrone (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. norethindrone levels, contraceptive efficacy (hepatic metab. induced)

• norgestimate (contraceptive)
Augtyro (repotrectinib)

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metab. induced)

• norgestrel (contraceptive)
Augtyro (repotrectinib)

+

norgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + norgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metab. induced)

• olaparib
Augtyro (repotrectinib)

+

olaparib

1 interaction

Avoid/Use Alternative

repotrectinib + olaparib

avoid combo: combo may decr. olaparib levels, efficacy (hepatic metab. induced)

• oliceridine
Augtyro (repotrectinib)

+

oliceridine

1 interaction

Avoid/Use Alternative

repotrectinib + oliceridine

use alternative or monitor resp. rate, BP, withdrawal sx; consider oliceridine dose adjustment, use lowest effective doses and shortest duration of concomitant tx: combo may decr. oliceridine levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension (hepatic metab. induced; additive effects)

• olutasidenib
Augtyro (repotrectinib)

+

olutasidenib

1 interaction

Avoid/Use Alternative

repotrectinib + olutasidenib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• omaveloxolone
Augtyro (repotrectinib)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

repotrectinib + omaveloxolone

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• osimertinib
Augtyro (repotrectinib)

+

osimertinib

1 interaction

Avoid/Use Alternative

repotrectinib + osimertinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. osimertinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• oxybate
Augtyro (repotrectinib)

+

oxybate

1 interaction

Avoid/Use Alternative

repotrectinib + oxybate

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects)

• oxycodone
Augtyro (repotrectinib)

+

oxycodone

1 interaction

Avoid/Use Alternative

repotrectinib + oxycodone

use alternative or monitor resp. rate, withdrawal sx; decr. oxycodone start dose by at least 50%, consider decr. repotrectinib dose, use lowest effective doses and shortest duration of concomitant tx: combo may decr. oxycodone levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• pacritinib
Augtyro (repotrectinib)

+

pacritinib

1 interaction

Avoid/Use Alternative

repotrectinib + pacritinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. levels of both drugs, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• palbociclib
Augtyro (repotrectinib)

+

palbociclib

1 interaction

Avoid/Use Alternative

repotrectinib + palbociclib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. palbociclib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• palovarotene
Augtyro (repotrectinib)

+

palovarotene

1 interaction

Avoid/Use Alternative

repotrectinib + palovarotene

avoid combo: combo may decr. palovarotene levels, efficacy (hepatic metab. induced)

• paroxetine
Augtyro (repotrectinib)

+

paroxetine

1 interaction

Avoid/Use Alternative

repotrectinib + paroxetine

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, adverse effects (P-gp-mediated transport inhibited, additive effects)

• pemigatinib
Augtyro (repotrectinib)

+

pemigatinib

1 interaction

Avoid/Use Alternative

repotrectinib + pemigatinib

avoid combo: combo may decr. pemigatinib levels, efficacy (hepatic metab. induced)

• pentobarbital
Augtyro (repotrectinib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

repotrectinib + pentobarbital

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• pexidartinib
Augtyro (repotrectinib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

repotrectinib + pexidartinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• phenelzine
Augtyro (repotrectinib)

+

phenelzine

1 interaction

Avoid/Use Alternative

repotrectinib + phenelzine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• phenobarbital
Augtyro (repotrectinib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

repotrectinib + phenobarbital

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• phenytoin
Augtyro (repotrectinib)

+

phenytoin

1 interaction

Avoid/Use Alternative

repotrectinib + phenytoin

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• pibrentasvir
Augtyro (repotrectinib)

+

pibrentasvir

1 interaction

Avoid/Use Alternative

repotrectinib + pibrentasvir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• pimavanserin
Augtyro (repotrectinib)

+

pimavanserin

1 interaction

Avoid/Use Alternative

repotrectinib + pimavanserin

avoid combo: combo may decr. pimavanserin levels, efficacy (hepatic metab. induced)

• pirtobrutinib
Augtyro (repotrectinib)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

repotrectinib + pirtobrutinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. pirtobrutinib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• ponatinib
Augtyro (repotrectinib)

+

ponatinib

1 interaction

Avoid/Use Alternative

repotrectinib + ponatinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ponatinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• posaconazole
Augtyro (repotrectinib)

+

posaconazole

1 interaction

Avoid/Use Alternative

repotrectinib + posaconazole

avoid combo; D/C posaconazole 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• pralsetinib
Augtyro (repotrectinib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

repotrectinib + pralsetinib

if adding pralsetinib to ongoing repotrectinib tx or 7 days after adding repotrectinib to ongoing pralsetinib tx, use alternative or incr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, incr. to 600 mg qd; if on pralsetinib 300 mg qd, incr. to 500 mg qd; if on pralsetinib 200 mg qd, incr. to 300 mg qd: combo may decr. pralsetinib levels, efficacy (hepatic metab. induced)

• praziquantel
Augtyro (repotrectinib)

+

praziquantel

1 interaction

Avoid/Use Alternative

repotrectinib + praziquantel

use alternative or D/C repotrectinib at least 2wk prior to praziquantel start; if immediate schistosomiasis tx required, monitor anthelmintic efficacy: combo may decr. praziquantel levels, efficacy (hepatic metab. induced)

• pretomanid
Augtyro (repotrectinib)

+

pretomanid

1 interaction

Avoid/Use Alternative

repotrectinib + pretomanid

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. pretomanid levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• primidone
Augtyro (repotrectinib)

+

primidone

1 interaction

Avoid/Use Alternative

repotrectinib + primidone

avoid combo: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• promethazine
Augtyro (repotrectinib)

+

promethazine

1 interaction

Avoid/Use Alternative

repotrectinib + promethazine

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• propafenone
Augtyro (repotrectinib)

+

propafenone

1 interaction

Avoid/Use Alternative

repotrectinib + propafenone

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. propafenone levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• quercetin
Augtyro (repotrectinib)

+

quercetin

1 interaction

Avoid/Use Alternative

repotrectinib + quercetin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• quinidine (antiarrhythmic)
Augtyro (repotrectinib)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

repotrectinib + quinidine (antiarrhythmic)

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. quinidine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• quinidine (CYP2D6 inhibitor)
Augtyro (repotrectinib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

repotrectinib + quinidine (CYP2D6 inhibitor)

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. quinidine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• quinine
Augtyro (repotrectinib)

+

quinine

1 interaction

Avoid/Use Alternative

repotrectinib + quinine

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. quinine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• quizartinib
Augtyro (repotrectinib)

+

quizartinib

1 interaction

Avoid/Use Alternative

repotrectinib + quizartinib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• revumenib
Augtyro (repotrectinib)

+

revumenib

1 interaction

Avoid/Use Alternative

repotrectinib + revumenib

avoid combo: combo may decr. revumenib levels, efficacy; may incr. revumenib active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. induced; incr. active metabolite formation)

• ribociclib
Augtyro (repotrectinib)

+

ribociclib

1 interaction

Avoid/Use Alternative

repotrectinib + ribociclib

avoid combo; D/C ribociclib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ribociclib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• rifabutin
Augtyro (repotrectinib)

+

rifabutin

1 interaction

Avoid/Use Alternative

repotrectinib + rifabutin

avoid combo: combo may decr. levels, efficacy of both drugs (hepatic metab. induced)

• rifampin
Augtyro (repotrectinib)

+

rifampin

1 interaction

Avoid/Use Alternative

repotrectinib + rifampin

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• rifapentine
Augtyro (repotrectinib)

+

rifapentine

1 interaction

Avoid/Use Alternative

repotrectinib + rifapentine

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• rilpivirine
Augtyro (repotrectinib)

+

rilpivirine

1 interaction

Avoid/Use Alternative

repotrectinib + rilpivirine

avoid combo: combo may decr. rilpivirine levels, efficacy (hepatic metab. induced)

• rimegepant
Augtyro (repotrectinib)

+

rimegepant

1 interaction

Avoid/Use Alternative

repotrectinib + rimegepant

avoid combo: combo may decr. rimegepant levels, efficacy (hepatic metab. induced)

• ripretinib
Augtyro (repotrectinib)

+

ripretinib

1 interaction

Avoid/Use Alternative

repotrectinib + ripretinib

use alternative or incr. ripretinib dose to 150 mg bid: combo may decr. ripretinib and active metabolite levels, efficacy (hepatic metab. induced)

• ritonavir
Augtyro (repotrectinib)

+

ritonavir

1 interaction

Avoid/Use Alternative

repotrectinib + ritonavir

avoid combo; D/C ritonavir 3-5 half-lives prior to repotrectinib tx: combo may decr. ritonavir levels, efficacy; may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced; P-gp-mediated transport inhibited, hepatic metab. altered)

• rivaroxaban
Augtyro (repotrectinib)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

repotrectinib + rivaroxaban

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. rivaroxaban levels, efficacy (hepatic metab. induced)

• roflumilast
Augtyro (repotrectinib)

+

roflumilast

1 interaction

Avoid/Use Alternative

repotrectinib + roflumilast

consider alternative: combo may decr. roflumilast levels, efficacy (hepatic metab. induced)

• rolapitant
Augtyro (repotrectinib)

+

rolapitant

1 interaction

Avoid/Use Alternative

repotrectinib + rolapitant

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. rolapitant levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• ropeginterferon alfa-2b
Augtyro (repotrectinib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

repotrectinib + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rucaparib
Augtyro (repotrectinib)

+

rucaparib

1 interaction

Avoid/Use Alternative

repotrectinib + rucaparib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• samidorphan
Augtyro (repotrectinib)

+

samidorphan

1 interaction

Avoid/Use Alternative

repotrectinib + samidorphan

consider alternative: combo may decr. samidorphan levels, efficacy (hepatic metab. induced)

• sarecycline
Augtyro (repotrectinib)

+

sarecycline

1 interaction

Avoid/Use Alternative

repotrectinib + sarecycline

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• sebetralstat
Augtyro (repotrectinib)

+

sebetralstat

1 interaction

Avoid/Use Alternative

repotrectinib + sebetralstat

avoid combo: combo may decr. sebetralstat levels, efficacy (hepatic metab. induced)

• segesterone (contraceptive)
Augtyro (repotrectinib)

+

segesterone (contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + segesterone (contraceptive)

use additional non-hormonal or alternative contraception during and x2mo after repotrectinib tx: combo may decr. segesterone levels, contraceptive efficacy (hepatic metab. induced)

• selpercatinib
Augtyro (repotrectinib)

+

selpercatinib

1 interaction

Avoid/Use Alternative

repotrectinib + selpercatinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. selpercatinib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• selumetinib
Augtyro (repotrectinib)

+

selumetinib

1 interaction

Avoid/Use Alternative

repotrectinib + selumetinib

avoid combo: combo may decr. selumetinib levels, efficacy (hepatic metab. induced)

• simvastatin
Augtyro (repotrectinib)

+

simvastatin

1 interaction

Avoid/Use Alternative

repotrectinib + simvastatin

consider alternative: combo may decr. simvastatin levels, efficacy (hepatic metab. induced)

• siponimod
Augtyro (repotrectinib)

+

siponimod

1 interaction

Avoid/Use Alternative

repotrectinib + siponimod

if CYP2C9 *1/*3 or *2/*3 genotype or if also combined w/ moderate or strong CYP2C9 inducer, avoid combo; otherwise, caution advised: combo may decr. siponimod levels, efficacy (hepatic metab. induced)

• sonidegib
Augtyro (repotrectinib)

+

sonidegib

1 interaction

Avoid/Use Alternative

repotrectinib + sonidegib

avoid combo: combo may decr. sonidegib levels, efficacy (hepatic metab. induced)

• sorafenib
Augtyro (repotrectinib)

+

sorafenib

1 interaction

Avoid/Use Alternative

repotrectinib + sorafenib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. sorafenib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• sotagliflozin
Augtyro (repotrectinib)

+

sotagliflozin

1 interaction

Avoid/Use Alternative

repotrectinib + sotagliflozin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• sotorasib
Augtyro (repotrectinib)

+

sotorasib

1 interaction

Avoid/Use Alternative

repotrectinib + sotorasib

avoid combo: combo may decr. levels of both drugs, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; P-gp-mediated transport inhibited)

• sparsentan
Augtyro (repotrectinib)

+

sparsentan

1 interaction

Avoid/Use Alternative

repotrectinib + sparsentan

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. sparsentan levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• St. John's wort
Augtyro (repotrectinib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

repotrectinib + St. John's wort

avoid combo: combo may decr. repotrectinib levels, efficacy (hepatic metab. induced)

• stiripentol
Augtyro (repotrectinib)

+

stiripentol

1 interaction

Avoid/Use Alternative

repotrectinib + stiripentol

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr. stiripentol levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. altered, P-gp-mediated transport inhibited; hepatic metab. possibly induced; additive effects)

• sufentanil
Augtyro (repotrectinib)

+

sufentanil

1 interaction

Avoid/Use Alternative

repotrectinib + sufentanil

use alternative or monitor resp. rate; consider sufentanil dose adjustment, use lowest effective doses and shortest duration of concomitant tx: combo may decr. sufentanil levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• sunvozertinib
Augtyro (repotrectinib)

+

sunvozertinib

1 interaction

Avoid/Use Alternative

repotrectinib + sunvozertinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. levels of both drugs, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• suvorexant
Augtyro (repotrectinib)

+

suvorexant

1 interaction

Avoid/Use Alternative

repotrectinib + suvorexant

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. suvorexant levels, efficacy (gut P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• suzetrigine
Augtyro (repotrectinib)

+

suzetrigine

1 interaction

Avoid/Use Alternative

repotrectinib + suzetrigine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• tacrolimus
Augtyro (repotrectinib)

+

tacrolimus

1 interaction

Avoid/Use Alternative

repotrectinib + tacrolimus

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. tacrolimus levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• tadalafil
Augtyro (repotrectinib)

+

tadalafil

1 interaction

Avoid/Use Alternative

repotrectinib + tadalafil

PULMONARY HTN: consider alternative; ERECTILE DYSFUNCTION and BENIGN PROSTATIC HYPERPLASIA: caution advised: combo may decr. tadalafil levels, efficacy (hepatic metab. induced)

• tamoxifen
Augtyro (repotrectinib)

+

tamoxifen

1 interaction

Avoid/Use Alternative

repotrectinib + tamoxifen

avoid combo: combo may decr. tamoxifen and active metabolite levels, efficacy (hepatic metab. induced)

• tasimelteon
Augtyro (repotrectinib)

+

tasimelteon

1 interaction

Avoid/Use Alternative

repotrectinib + tasimelteon

consider alternative: combo may decr. tasimelteon levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• tazemetostat
Augtyro (repotrectinib)

+

tazemetostat

1 interaction

Avoid/Use Alternative

repotrectinib + tazemetostat

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• telmisartan
Augtyro (repotrectinib)

+

telmisartan

1 interaction

Avoid/Use Alternative

repotrectinib + telmisartan

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• temsirolimus
Augtyro (repotrectinib)

+

temsirolimus

1 interaction

Avoid/Use Alternative

repotrectinib + temsirolimus

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. temsirolimus and active metabolite sirolimus levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• tepotinib
Augtyro (repotrectinib)

+

tepotinib

1 interaction

Avoid/Use Alternative

repotrectinib + tepotinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• tezacaftor/ivacaftor
Augtyro (repotrectinib)

+

tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

repotrectinib + tezacaftor/ ivacaftor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. tezacaftor/ivacaftor levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• thalidomide
Augtyro (repotrectinib)

+

thalidomide

1 interaction

Avoid/Use Alternative

repotrectinib + thalidomide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Augtyro (repotrectinib)

+

thiotepa

1 interaction

Avoid/Use Alternative

repotrectinib + thiotepa

use alternative or monitor CBC: combo may decr. thiotepa levels, efficacy; may incr. thiotepa active metabolite levels, risk of serious infection, myelosuppression, other adverse effects; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced, incr. metabolite formation; additive effects)

• ticagrelor
Augtyro (repotrectinib)

+

ticagrelor

1 interaction

Avoid/Use Alternative

repotrectinib + ticagrelor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. ticagrelor levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• tipranavir
Augtyro (repotrectinib)

+

tipranavir

1 interaction

Avoid/Use Alternative

repotrectinib + tipranavir

avoid combo; D/C tipranavir 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. tipranavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• tofacitinib
Augtyro (repotrectinib)

+

tofacitinib

1 interaction

Avoid/Use Alternative

repotrectinib + tofacitinib

consider alternative: combo may decr. tofacitinib levels, efficacy (hepatic metab. induced)

• tolvaptan
Augtyro (repotrectinib)

+

tolvaptan

1 interaction

Avoid/Use Alternative

repotrectinib + tolvaptan

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. tolvaptan levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• toremifene
Augtyro (repotrectinib)

+

toremifene

1 interaction

Avoid/Use Alternative

repotrectinib + toremifene

avoid combo: combo may decr. toremifene levels, efficacy (hepatic metab. induced)

• tramadol
Augtyro (repotrectinib)

+

tramadol

1 interaction

Avoid/Use Alternative

repotrectinib + tramadol

use alternative or monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. tramadol levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• tranylcypromine
Augtyro (repotrectinib)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

repotrectinib + tranylcypromine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trazodone
Augtyro (repotrectinib)

+

trazodone

1 interaction

Avoid/Use Alternative

repotrectinib + trazodone

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. trazodone levels, efficacy (P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• trimethobenzamide
Augtyro (repotrectinib)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

repotrectinib + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimethoprim
Augtyro (repotrectinib)

+

trimethoprim

1 interaction

Avoid/Use Alternative

repotrectinib + trimethoprim

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• tucatinib
Augtyro (repotrectinib)

+

tucatinib

1 interaction

Avoid/Use Alternative

repotrectinib + tucatinib

avoid combo; D/C tucatinib 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. tucatinib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• turmeric
Augtyro (repotrectinib)

+

turmeric

1 interaction

Avoid/Use Alternative

repotrectinib + turmeric

avoid combo w/ oral turmeric: combo may incr. repotrectinib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• ulipristal (post-coital contraceptive)
Augtyro (repotrectinib)

+

ulipristal (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

repotrectinib + ulipristal (post-coital contraceptive)

avoid combo: combo may decr. ulipristal levels, post-coital contraceptive efficacy (hepatic metab. induced)

• uridine triacetate
Augtyro (repotrectinib)

+

uridine triacetate

1 interaction

Avoid/Use Alternative

repotrectinib + uridine triacetate

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

• valbenazine
Augtyro (repotrectinib)

+

valbenazine

1 interaction

Avoid/Use Alternative

repotrectinib + valbenazine

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. induced; P-gp-mediated transport inhibited, additive effects)

• vandetanib
Augtyro (repotrectinib)

+

vandetanib

1 interaction

Avoid/Use Alternative

repotrectinib + vandetanib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. vandetanib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• vanzacaftor/tezacaftor/deutivacaftor
Augtyro (repotrectinib)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Avoid/Use Alternative

repotrectinib + vanzacaftor/ tezacaftor/ deutivacaftor

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. vanzacaftor/tezacaftor/deutivacaftor levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• velpatasvir
Augtyro (repotrectinib)

+

velpatasvir

1 interaction

Avoid/Use Alternative

repotrectinib + velpatasvir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. velpatasvir levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• vemurafenib
Augtyro (repotrectinib)

+

vemurafenib

1 interaction

Avoid/Use Alternative

repotrectinib + vemurafenib

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr. vemurafenib levels, efficacy (P-gp-mediated transport inhibited, hepatic metab. induced; hepatic metab. induced)

• venetoclax
Augtyro (repotrectinib)

+

venetoclax

1 interaction

Avoid/Use Alternative

repotrectinib + venetoclax

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. venetoclax levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• verapamil
Augtyro (repotrectinib)

+

verapamil

1 interaction

Avoid/Use Alternative

repotrectinib + verapamil

avoid combo; D/C verapamil 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. verapamil levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• vilazodone
Augtyro (repotrectinib)

+

vilazodone

1 interaction

Avoid/Use Alternative

repotrectinib + vilazodone

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. vilazodone levels, efficacy (P-gp-mediated transport inhibited, additive effects; hepatic metab. induced)

• vimseltinib
Augtyro (repotrectinib)

+

vimseltinib

1 interaction

Avoid/Use Alternative

repotrectinib + vimseltinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• voclosporin
Augtyro (repotrectinib)

+

voclosporin

1 interaction

Avoid/Use Alternative

repotrectinib + voclosporin

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. voclosporin levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• vonoprazan
Augtyro (repotrectinib)

+

vonoprazan

1 interaction

Avoid/Use Alternative

repotrectinib + vonoprazan

avoid combo: combo may decr. vonoprazan levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• voriconazole
Augtyro (repotrectinib)

+

voriconazole

1 interaction

Avoid/Use Alternative

repotrectinib + voriconazole

avoid combo; D/C voriconazole 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. voriconazole levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• voxelotor
Augtyro (repotrectinib)

+

voxelotor

1 interaction

Avoid/Use Alternative

repotrectinib + voxelotor

ADULTS or >12 YO: use alternative or incr. voxelotor dose to 2000 mg qd; PEDS: use alternative or incr. voxelotor dose as follows: if wt >40 kg, incr. voxelotor dose to 2000-2100 mg qd; if wt 20-39 kg, incr. voxelotor dose to 1200 mg qd; if wt 10-19 kg, incr. voxelotor dose to 900 mg qd: combo may decr. voxelotor levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• voxilaprevir
Augtyro (repotrectinib)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

repotrectinib + voxilaprevir

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. voxilaprevir levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• xanomeline
Augtyro (repotrectinib)

+

xanomeline

1 interaction

Avoid/Use Alternative

repotrectinib + xanomeline

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (GI metab. possibly inhibited, gut P-gp-mediated transport possibly inhibited)

• zanubrutinib
Augtyro (repotrectinib)

+

zanubrutinib

1 interaction

Avoid/Use Alternative

repotrectinib + zanubrutinib

use alternative or incr. zanubrutinib dose to 320 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• zonisamide
Augtyro (repotrectinib)

+

zonisamide

1 interaction

Avoid/Use Alternative

repotrectinib + zonisamide

avoid combo: combo may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects; may decr. zonisamide levels, efficacy (P-gp-mediated transport possibly inhibited, additive effects; hepatic metab. induced)

• zuranolone
Augtyro (repotrectinib)

+

zuranolone

1 interaction

Avoid/Use Alternative

repotrectinib + zuranolone

avoid combo: combo may decr. zuranolone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

Monitor/Modify Tx

• abiraterone acetate
Augtyro (repotrectinib)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

repotrectinib + abiraterone acetate

if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metab. induced)

• acalabrutinib
Augtyro (repotrectinib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

repotrectinib + acalabrutinib

consider acalabrutinib dose adjustment: combo may decr. acalabrutinib levels, efficacy (hepatic metab. induced)

• aldesleukin
Augtyro (repotrectinib)

+

aldesleukin

1 interaction

Monitor/Modify Tx

repotrectinib + aldesleukin

withhold aldesleukin if mod-severe somnolence occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• allopurinol
Augtyro (repotrectinib)

+

allopurinol

1 interaction

Monitor/Modify Tx

repotrectinib + allopurinol

monitor uric acid: combo may decr. allopurinol efficacy; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects; additive effects)

• alprazolam
Augtyro (repotrectinib)

+

alprazolam

1 interaction

Monitor/Modify Tx

repotrectinib + alprazolam

monitor resp. rate: combo may incr. repotrectinib levels, risk of adverse effects; may decr. alprazolam levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. inhibited; hepatic metab. induced; additive effects)

• aminophylline
Augtyro (repotrectinib)

+

aminophylline

1 interaction

Monitor/Modify Tx

repotrectinib + aminophylline

monitor theophylline levels: combo may decr. theophylline levels, efficacy (hepatic metab. induced, aminophylline converted to theophylline)

• amlodipine
Augtyro (repotrectinib)

+

amlodipine

1 interaction

Monitor/Modify Tx

repotrectinib + amlodipine

monitor BP: combo may decr. (lev)amlodipine levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• avatrombopag
Augtyro (repotrectinib)

+

avatrombopag

1 interaction

Monitor/Modify Tx

repotrectinib + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: if also combined w/ mod-strong CYP2C9 inducer, incr. start dose to 40 mg po qd and monitor platelets; otherwise, monitor platelets; CHRONIC LIVER DZ: monitor platelets: combo may decr. avatrombopag levels, efficacy (hepatic metab. induced)

• baclofen intrathecal
Augtyro (repotrectinib)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

repotrectinib + baclofen intrathecal

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• betamethasone
Augtyro (repotrectinib)

+

betamethasone

1 interaction

Monitor/Modify Tx

repotrectinib + betamethasone

consider betamethasone dose adjustment: combo may decr. betamethasone levels, efficacy (hepatic metab. induced)

• brexpiprazole
Augtyro (repotrectinib)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

repotrectinib + brexpiprazole

consider incr. brexpiprazole dose: combo may decr. brexpiprazole levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• butorphanol
Augtyro (repotrectinib)

+

butorphanol

1 interaction

Monitor/Modify Tx

repotrectinib + butorphanol

monitor resp. rate, withdrawal sx; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may decr. butorphanol levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• calcitriol
Augtyro (repotrectinib)

+

calcitriol

1 interaction

Monitor/Modify Tx

repotrectinib + calcitriol

monitor vitamin D levels: combo may decr. vitamin D levels, efficacy (hepatic metab. induced)

• chlordiazepoxide
Augtyro (repotrectinib)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

repotrectinib + chlordiazepoxide

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chlorpromazine
Augtyro (repotrectinib)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

repotrectinib + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cholecalciferol (vitamin D3)
Augtyro (repotrectinib)

+

cholecalciferol (vitamin D3)

1 interaction

Monitor/Modify Tx

repotrectinib + cholecalciferol (vitamin D3)

monitor vitamin D levels: combo may decr. vitamin D levels, efficacy (hepatic metab. induced)

• clobazam
Augtyro (repotrectinib)

+

clobazam

1 interaction

Monitor/Modify Tx

repotrectinib + clobazam

monitor resp. rate: combo may decr. repotrectinib levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• clonazepam
Augtyro (repotrectinib)

+

clonazepam

1 interaction

Monitor/Modify Tx

repotrectinib + clonazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clorazepate
Augtyro (repotrectinib)

+

clorazepate

1 interaction

Monitor/Modify Tx

repotrectinib + clorazepate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clozapine
Augtyro (repotrectinib)

+

clozapine

1 interaction

Monitor/Modify Tx

repotrectinib + clozapine

consider incr. clozapine dose: combo may decr. clozapine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• crinecerfont
Augtyro (repotrectinib)

+

crinecerfont

1 interaction

Monitor/Modify Tx

repotrectinib + crinecerfont

ADULTS: keep 100 mg morning dose unchanged, incr. crinecerfont evening dose to 200 mg; PEDS 4 YO AND OLDER: incr. crinecerfont dose based on weight as follows: if 10-19 kg, keep 25 mg morning dose unchanged, incr. crinecerfont evening dose to 50 mg; if 20-54 kg, keep 50 mg morning dose unchanged, incr. crinecerfont evening dose to 100 mg; if 55 kg or greater, keep 100 mg morning dose unchanged, incr. crinecerfont evening dose to 200 mg: combo may decr. crinecerfont levels, efficacy (hepatic metab. induced)

• cyclophosphamide
Augtyro (repotrectinib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

repotrectinib + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metab. possibly induced, incr. active metabolite formation)

• desflurane
Augtyro (repotrectinib)

+

desflurane

1 interaction

Monitor/Modify Tx

repotrectinib + desflurane

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• dexmedetomidine
Augtyro (repotrectinib)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

repotrectinib + dexmedetomidine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Augtyro (repotrectinib)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

repotrectinib + dexmedetomidine injection

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• diazepam
Augtyro (repotrectinib)

+

diazepam

1 interaction

Monitor/Modify Tx

repotrectinib + diazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may decr. diazepam levels, efficacy; may incr. risk of profound CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• disopyramide
Augtyro (repotrectinib)

+

disopyramide

1 interaction

Monitor/Modify Tx

repotrectinib + disopyramide

monitor disopyramide levels: combo may decr. disopyramide levels, efficacy (hepatic metab. induced)

• doxercalciferol
Augtyro (repotrectinib)

+

doxercalciferol

1 interaction

Monitor/Modify Tx

repotrectinib + doxercalciferol

monitor calcium, iPTH: combo may alter doxercalciferol and active metabolite levels, efficacy (hepatic metab. induced, net effect on vitamin D activation/inactivation unknown)

• droperidol
Augtyro (repotrectinib)

+

droperidol

1 interaction

Monitor/Modify Tx

repotrectinib + droperidol

decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• esketamine
Augtyro (repotrectinib)

+

esketamine

1 interaction

Monitor/Modify Tx

repotrectinib + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• estazolam
Augtyro (repotrectinib)

+

estazolam

1 interaction

Monitor/Modify Tx

repotrectinib + estazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• eszopiclone
Augtyro (repotrectinib)

+

eszopiclone

1 interaction

Monitor/Modify Tx

repotrectinib + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may decr. eszopiclone levels, efficacy (additive effects; hepatic metab. induced)

• ethanol (in some formulations)
Augtyro (repotrectinib)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

repotrectinib + ethanol (in some formulations)

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• ethosuximide
Augtyro (repotrectinib)

+

ethosuximide

1 interaction

Monitor/Modify Tx

repotrectinib + ethosuximide

monitor ethosuximide levels: combo may decr. ethosuximide levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• etomidate
Augtyro (repotrectinib)

+

etomidate

1 interaction

Monitor/Modify Tx

repotrectinib + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• febuxostat
Augtyro (repotrectinib)

+

febuxostat

1 interaction

Monitor/Modify Tx

repotrectinib + febuxostat

monitor uric acid: combo may decr. febuxostat efficacy (antagonistic effects)

• fludrocortisone
Augtyro (repotrectinib)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

repotrectinib + fludrocortisone

consider fludrocortisone dose adjustment: combo may decr. fludrocortisone levels, efficacy (hepatic metab. induced)

• fluphenazine
Augtyro (repotrectinib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

repotrectinib + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• flurazepam
Augtyro (repotrectinib)

+

flurazepam

1 interaction

Monitor/Modify Tx

repotrectinib + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin
Augtyro (repotrectinib)

+

gabapentin

1 interaction

Monitor/Modify Tx

repotrectinib + gabapentin

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Augtyro (repotrectinib)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

repotrectinib + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• guanfacine
Augtyro (repotrectinib)

+

guanfacine

1 interaction

Monitor/Modify Tx

repotrectinib + guanfacine

consider incr. guanfacine ER dose up to double, consider incr. dose for immed.-release form: combo may decr. guanfacine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced, additive effects)

• haloperidol
Augtyro (repotrectinib)

+

haloperidol

1 interaction

Monitor/Modify Tx

repotrectinib + haloperidol

consider haloperidol dose adjustment: combo may decr. haloperidol levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• hydrocortisone
Augtyro (repotrectinib)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

repotrectinib + hydrocortisone

consider hydrocortisone dose adjustment: combo may decr. hydrocortisone levels, efficacy (hepatic metab. induced)

• hydromorphone
Augtyro (repotrectinib)

+

hydromorphone

1 interaction

Monitor/Modify Tx

repotrectinib + hydromorphone

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• hydroxyzine
Augtyro (repotrectinib)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

repotrectinib + hydroxyzine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ifosfamide
Augtyro (repotrectinib)

+

ifosfamide

1 interaction

Monitor/Modify Tx

repotrectinib + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment; D/C one or both drugs if encephalopathy occurs: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. induced, incr. metabolite formation; additive effects)

• imipramine
Augtyro (repotrectinib)

+

imipramine

1 interaction

Monitor/Modify Tx

repotrectinib + imipramine

monitor imipramine levels: combo may decr. imipramine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• isoflurane
Augtyro (repotrectinib)

+

isoflurane

1 interaction

Monitor/Modify Tx

repotrectinib + isoflurane

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• ketamine
Augtyro (repotrectinib)

+

ketamine

1 interaction

Monitor/Modify Tx

repotrectinib + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (incl. life-threatening), psychomotor impairment (additive effects)

• levorphanol
Augtyro (repotrectinib)

+

levorphanol

1 interaction

Monitor/Modify Tx

repotrectinib + levorphanol

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lorazepam
Augtyro (repotrectinib)

+

lorazepam

1 interaction

Monitor/Modify Tx

repotrectinib + lorazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lurasidone
Augtyro (repotrectinib)

+

lurasidone

1 interaction

Monitor/Modify Tx

repotrectinib + lurasidone

consider lurasidone dose adjustment: combo may decr. lurasidone levels, efficacy; may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. induced; hepatic metab. inhibited, additive effects)

• macimorelin
Augtyro (repotrectinib)

+

macimorelin

1 interaction

Monitor/Modify Tx

repotrectinib + macimorelin

D/C repotrectinib, allowing sufficient washout time before diagnostic test: combo may decr. macimorelin levels, result in false positive test (hepatic metab. induced)

• methohexital
Augtyro (repotrectinib)

+

methohexital

1 interaction

Monitor/Modify Tx

repotrectinib + methohexital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• mirtazapine
Augtyro (repotrectinib)

+

mirtazapine

1 interaction

Monitor/Modify Tx

repotrectinib + mirtazapine

consider mirtazapine dose adjustment: combo may decr. mirtazapine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• morphine
Augtyro (repotrectinib)

+

morphine

1 interaction

Monitor/Modify Tx

repotrectinib + morphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• nalbuphine
Augtyro (repotrectinib)

+

nalbuphine

1 interaction

Monitor/Modify Tx

repotrectinib + nalbuphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• nelarabine
Augtyro (repotrectinib)

+

nelarabine

1 interaction

Monitor/Modify Tx

repotrectinib + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nimodipine
Augtyro (repotrectinib)

+

nimodipine

1 interaction

Monitor/Modify Tx

repotrectinib + nimodipine

monitor BP: combo may decr. nimodipine levels, efficacy (hepatic metab. induced)

• nortriptyline
Augtyro (repotrectinib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

repotrectinib + nortriptyline

monitor nortriptyline levels: combo may decr. nortriptyline levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• olanzapine
Augtyro (repotrectinib)

+

olanzapine

1 interaction

Monitor/Modify Tx

repotrectinib + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, incl. orthostasis (additive effects)

• opicapone
Augtyro (repotrectinib)

+

opicapone

1 interaction

Monitor/Modify Tx

repotrectinib + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Augtyro (repotrectinib)

+

opium

1 interaction

Monitor/Modify Tx

repotrectinib + opium

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• oxazepam
Augtyro (repotrectinib)

+

oxazepam

1 interaction

Monitor/Modify Tx

repotrectinib + oxazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• oxybutynin
Augtyro (repotrectinib)

+

oxybutynin

1 interaction

Monitor/Modify Tx

repotrectinib + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely w/ oxybutynin transdermal patch (additive effects)

• oxymorphone
Augtyro (repotrectinib)

+

oxymorphone

1 interaction

Monitor/Modify Tx

repotrectinib + oxymorphone

monitor resp. rate; decr. oxymorphone start dose by at least 50%, consider decr. oxymorphone dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• pegloticase
Augtyro (repotrectinib)

+

pegloticase

1 interaction

Monitor/Modify Tx

repotrectinib + pegloticase

monitor uric acid levels: combo may decr. pegloticase efficacy (antagonistic effects)

• pentazocine
Augtyro (repotrectinib)

+

pentazocine

1 interaction

Monitor/Modify Tx

repotrectinib + pentazocine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• perampanel
Augtyro (repotrectinib)

+

perampanel

1 interaction

Monitor/Modify Tx

repotrectinib + perampanel

incr. perampanel start dose to 4 mg/day: combo may decr. perampanel levels, efficacy; may decr. repotrectinib levels, efficacy if on perampanel 12 mg/day; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• perphenazine
Augtyro (repotrectinib)

+

perphenazine

1 interaction

Monitor/Modify Tx

repotrectinib + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pregabalin
Augtyro (repotrectinib)

+

pregabalin

1 interaction

Monitor/Modify Tx

repotrectinib + pregabalin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• probenecid
Augtyro (repotrectinib)

+

probenecid

1 interaction

Monitor/Modify Tx

repotrectinib + probenecid

monitor uric acid levels: combo may decr. probenecid efficacy (antagonistic effects)

• propofol
Augtyro (repotrectinib)

+

propofol

1 interaction

Monitor/Modify Tx

repotrectinib + propofol

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quazepam
Augtyro (repotrectinib)

+

quazepam

1 interaction

Monitor/Modify Tx

repotrectinib + quazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quetiapine
Augtyro (repotrectinib)

+

quetiapine

1 interaction

Monitor/Modify Tx

repotrectinib + quetiapine

consider quetiapine dose adjustment: combo may decr. quetiapine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• rasburicase
Augtyro (repotrectinib)

+

rasburicase

1 interaction

Monitor/Modify Tx

repotrectinib + rasburicase

monitor uric acid levels: combo may decr. rasburicase efficacy (antagonistic effects)

• remifentanil
Augtyro (repotrectinib)

+

remifentanil

1 interaction

Monitor/Modify Tx

repotrectinib + remifentanil

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• remimazolam
Augtyro (repotrectinib)

+

remimazolam

1 interaction

Monitor/Modify Tx

repotrectinib + remimazolam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• repaglinide
Augtyro (repotrectinib)

+

repaglinide

1 interaction

Monitor/Modify Tx

repotrectinib + repaglinide

monitor glucose: combo may decr. repaglinide levels, efficacy (hepatic metab. induced)

• sevoflurane
Augtyro (repotrectinib)

+

sevoflurane

1 interaction

Monitor/Modify Tx

repotrectinib + sevoflurane

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• sildenafil
Augtyro (repotrectinib)

+

sildenafil

1 interaction

Monitor/Modify Tx

repotrectinib + sildenafil

PULMONARY HTN: consider sildenafil dose adjustment; ED: caution advised: combo may decr. sildenafil levels, efficacy (hepatic metab. induced)

• sirolimus
Augtyro (repotrectinib)

+

sirolimus

1 interaction

Monitor/Modify Tx

repotrectinib + sirolimus

monitor sirolimus levels: combo may decr. sirolimus levels, efficacy (hepatic metab. induced)

• tapentadol
Augtyro (repotrectinib)

+

tapentadol

1 interaction

Monitor/Modify Tx

repotrectinib + tapentadol

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• temazepam
Augtyro (repotrectinib)

+

temazepam

1 interaction

Monitor/Modify Tx

repotrectinib + temazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• theophylline
Augtyro (repotrectinib)

+

theophylline

1 interaction

Monitor/Modify Tx

repotrectinib + theophylline

monitor theophylline levels: combo may decr. theophylline levels, efficacy (hepatic metab. induced)

• thioridazine
Augtyro (repotrectinib)

+

thioridazine

1 interaction

Monitor/Modify Tx

repotrectinib + thioridazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiothixene
Augtyro (repotrectinib)

+

thiothixene

1 interaction

Monitor/Modify Tx

repotrectinib + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tiagabine
Augtyro (repotrectinib)

+

tiagabine

1 interaction

Monitor/Modify Tx

repotrectinib + tiagabine

consider tiagabine dose adjustment if not on concurrent enzyme-inducing AEDs; titrate tiagabine dose to effect if already on enzyme-inducing AEDs: combo may decr. tiagabine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; further induction possible if on concurrent enzyme-inducing AEDs; additive effects)

• triazolam
Augtyro (repotrectinib)

+

triazolam

1 interaction

Monitor/Modify Tx

repotrectinib + triazolam

monitor resp. rate: combo may decr. triazolam levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• ubrogepant
Augtyro (repotrectinib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

repotrectinib + ubrogepant

increase ubrogepant dose to 100 mg, may give second 100 mg dose after 2h if needed: combo may decr. ubrogepant levels, efficacy (hepatic metab. induced)

• vortioxetine
Augtyro (repotrectinib)

+

vortioxetine

1 interaction

Monitor/Modify Tx

repotrectinib + vortioxetine

consider vortioxetine dose adjustment: combo may decr. vortioxetine levels, efficacy (hepatic metab. induced)

• warfarin
Augtyro (repotrectinib)

+

warfarin

1 interaction

Monitor/Modify Tx

repotrectinib + warfarin

monitor INR: combo may decr. warfarin levels, efficacy (hepatic metab. induced)

• zaleplon
Augtyro (repotrectinib)

+

zaleplon

1 interaction

Monitor/Modify Tx

repotrectinib + zaleplon

consider decr. dose of one or both drugs: combo may decr. zaleplon levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• ziconotide
Augtyro (repotrectinib)

+

ziconotide

1 interaction

Monitor/Modify Tx

repotrectinib + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Augtyro (repotrectinib)

+

zolpidem

1 interaction

Monitor/Modify Tx

repotrectinib + zolpidem

consider decr. dose of one or both drugs: combo may decr. zolpidem levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)